PTEN and PI-3 kinase inhibitors control LPS signaling and the lymphoproliferative response in the CD19+ B cell compartment

Experimental Cell Research

Volumn 327, Issue 1, 2014, Pages 78-90

  Singh, Alok R ^a   Peirce, Susan K ^b   Joshi, Shweta ^a   Durden, Donald L ^a,c  

^a UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

^b EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c RADY CHILDREN'S HOSPITAL   (United States)

Author keywords

AKT; B cells; CD19; Lymphoid; NF B; PI 3 kinase; PTEN; TLR

Indexed keywords

CRE RECOMBINASE; CYCLIN D1; GENOMIC DNA; INTERLEUKIN 14; INTERLEUKIN 14A; LIPOPOLYSACCHARIDE; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PROTEIN KINASE B; UNCLASSIFIED DRUG; [1 (4 OXO 8 PHENYL 4H 1 BENZOPYRAN 2 YL)MORPHOLINIO]METHOXYSUCCINYLARGINYLGLYCYLASPARTYLSERINE ACETATE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; B LYMPHOCYTE; CD 19 POSITIVE B LYMPHOCYTE; CELL COMPARTMENTALIZATION; CELL CYCLE ARREST; CELL GROWTH; CONTROLLED STUDY; DRUG EFFECT; GENOTYPE; IMMUNOBLOTTING; IN VITRO STUDY; IN VIVO STUDY; KNOCKOUT MOUSE; LYMPHOCYTE FUNCTION; LYMPHOCYTE PROLIFERATION; MICROARRAY ANALYSIS; MOUSE; NONHUMAN; ONCOGENE C MYC; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; PROTEIN DEPLETION; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; PROTEIN TARGETING; REAL TIME POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; SPLENOMEGALY; TRANSGENIC MOUSE; WESTERN BLOTTING;

AKT; B CELLS; CD19; LYMPHOID; NF-ΚB; PI-3 KINASE; PTEN; TLR;

ANIMALS; ANTIGENS, CD; ANTIGENS, CD19; B-LYMPHOCYTES; CELL PROLIFERATION; CHROMONES; CYCLIN D1; INTERLEUKINS; LIPOPOLYSACCHARIDES; LYMPHOCYTE ACTIVATION; MICE; MICE, INBRED BALB C; MICE, INBRED C57BL; MICE, KNOCKOUT; MICE, TRANSGENIC; NF-KAPPA B; OLIGOPEPTIDES; PHOSPHATIDYLINOSITOL 3-KINASES; PROTO-ONCOGENE PROTEINS C-MYB; PTEN PHOSPHOHYDROLASE; SIGNAL TRANSDUCTION; TOLL-LIKE RECEPTOR 4;

EID: 84906482400     PISSN: 00144827     EISSN: 10902422     Source Type: Journal    
DOI: 10.1016/j.yexcr.2014.05.016     Document Type: Article

References (50)

1. Ogata H., Su I., Miyake K., Nagai Y., Akashi S., Mecklenbrauker I., Rajewsky K., Kimoto M., Tarakhovsky A. The toll-like receptor protein RP105 regulates lipopolysaccharide signaling in B cells. J. Exp. Med. 2000, 192:23-29.
2. Yazawa N., Fujimoto M., Sato S., Miyake K., Asano N., Nagai Y., Takeuchi O., Takeda K., Okochi H., Akira S., Tedder T.F., Tamaki K. CD19 regulates innate immunity by the toll-like receptor RP105 signaling in B lymphocytes. Blood 2003, 102:1374-1380.
3. Pasare C., Medzhitov R. Control of B-cell responses by toll-like receptors. Nature 2005, 438:364-368.
4. Ha S.A., Tsuji M., Suzuki K., Meek B., Yasuda N., Kaisho T., Fagarasan S. Regulation of B1 cell migration by signals through Toll-like receptors. J. Exp. Med. 2006, 203:2541-2550.
5. Akira S., Uematsu S., Takeuchi O. Pathogen recognition and innate immunity. Cell 2006, 124:783-801.
6. Guttridge D.C., Albanese C., Reuther J.Y., Pestell R.G., Baldwin A.S. NF-kappaB controls cell growth and differentiation through transcriptional regulation of cyclin D1. Mol. Cell. Biol. 1999, 19:5785-5799.
7. Duyao M.P., Buckler A.J., Sonenshein G.E. Interaction of an NF-kappa B-like factor with a site upstream of the c-myc promoter. Proc. Natl. Acad. Sci. U. S. A. 1990, 87:4727-4731.
8. Barrio L., Saez de Guinoa J., Carrasco Y.R. TLR4 signaling shapes B cell dynamics via MyD88-dependent pathways and Rac GTPases. J. Immunol 2013, 191:3867-3875.
9. Hwang I.Y., Park C., Harrison K., Kehrl J.H. TLR4 signaling augments B lymphocyte migration and overcomes the restriction that limits access to germinal center dark zones. J. Exp. Med. 2009, 206:2641-2657.
10. Lee J.O., Yang H., Georgescu M.M., Di Cristofano A., Maehama T., Shi Y., Dixon J.E., Pandolfi P., Pavletich N.P. Crystal structure of the PTEN tumor suppressor: implications for its phosphoinositide phosphatase activity and membrane association. Cell 1999, 99:323-334.
11. Maehama T., Dixon J.E. The tumor suppressor, PTEN/MMAC1, dephosphorylates the lipid second messenger, phosphatidylinositol 3,4,5-trisphosphate. J. Biol. Chem. 1998, 273:13375-13378.
12. Gunzl P., Schabbauer G. Recent advances in the genetic analysis of PTEN and PI3K innate immune properties. Immunobiology 2008, 213:759-765.
13. Stocker H., Andjelkovic M., Oldham S., Laffargue M., Wymann M.P., Hemmings B.A., Hafen E. Living with lethal PIP3 levels: viability of flies lacking PTEN restored by a PH domain mutation in Akt/PKB. Science 2002, 295:2088-2091.
14. Li X., Tupper J.C., Bannerman D.D., Winn R.K., Rhodes C.J., Harlan J.M. Phosphoinositide 3 kinase mediates toll-like receptor 4-induced activation of NF-kappa B in endothelial cells. Infect. Immun. 2003, 71:4414-4420.
15. Laird M.H., Rhee S.H., Perkins D.J., Medvedev A.E., Piao W., Fenton M.J., Vogel S.N. TLR4/MyD88/PI3K interactions regulate TLR4 signaling. J. Leukoc. Biol. 2009, 85:966-977.
16. Ojaniemi M., Glumoff V., Harju K., Liljeroos M., Vuori K., Hallman M. Phosphatidylinositol 3-kinase is involved in toll-like receptor 4-mediated cytokine expression in mouse macrophages. Eur. J. Immunol. 2003, 33:597-605.
17. Jones B.W., Heldwein K.A., Means T.K., Saukkonen J.J., Fenton M.J. Differential roles of toll-like receptors in the elicitation of proinflammatory responses by macrophages. Ann. Rheum. Dis. 2001, 60(Suppl 3):iii6-12.
18. Akira S., Hoshino K. Myeloid differentiation factor 88-dependent and -independent pathways in toll-like receptor signaling. J. Infect. Dis. 2003, 187(Suppl 2):S356-S363.
19. Cao X., Wei G., Fang H., Guo J., Weinstein M., Marsh C.B., Ostrowski M.C., Tridandapani S. The inositol 3-phosphatase PTEN negatively regulates Fc gamma receptor signaling, but supports toll-like receptor 4 signaling in murine peritoneal macrophages. J. Immunol. 2004, 172:4851-4857.
20. Kamo N., Ke B., Busuttil R.W., Kupiec-Weglinski J.W. PTEN-mediated Akt/beta-catenin/Foxo1 signaling regulates innate immune responses in mouse liver ischemia/reperfusion injury. Hepatology 2013, 57:289-298.
21. Lee J.Y., Ye J., Gao Z., Youn H.S., Lee W.H., Zhao L., Sizemore N., Hwang D.H. Reciprocal modulation of toll-like receptor-4 signaling pathways involving MyD88 and phosphatidylinositol 3-kinase/AKT by saturated and polyunsaturated fatty acids. J. Biol. Chem. 2003, 278:37041-37051.
22. Luyendyk J.P., Schabbauer G.A., Tencati M., Holscher T., Pawlinski R., Mackman N. Genetic analysis of the role of the PI3K-Akt pathway in lipopolysaccharide-induced cytokine and tissue factor gene expression in monocytes/macrophages. J. Immunol. 2008, 180:4218-4226.
23. Fruman D.A., Snapper S.B., Yballe C.M., Davidson L., Yu J.Y., Alt F.W., Cantley L.C. Impaired B cell development and proliferation in absence of phosphoinositide 3-kinase p85alpha. Science 1999, 283:393-397.
24. Suzuki H., Terauchi Y., Fujiwara M., Aizawa S., Yazaki Y., Kadowaki T., Koyasu S. Xid-like immunodeficiency in mice with disruption of the p85alpha subunit of phosphoinositide 3-kinase. Science 1999, 283:390-392.
25. Clayton E., Bardi G., Bell S.E., Chantry D., Downes C.P., Gray A., Humphries L.A., Rawlings D., Reynolds H., Vigorito E., Turner M. A crucial role for the p110delta subunit of phosphatidylinositol 3-kinase in B cell development and activation. J. Exp. Med. 2002, 196:753-763.
26. Omori S.A., Cato M.H., Anzelon-Mills A., Puri K.D., Shapiro-Shelef M., Calame K., Rickert R.C. Regulation of class-switch recombination and plasma cell differentiation by phosphatidylinositol 3-kinase signaling. Immunity 2006, 25:545-557.
27. Suzuki A., Kaisho T., Ohishi M., Tsukio-Yamaguchi M., Tsubata T., Koni P.A., Sasaki T., Mak T.W., Nakano T. Critical roles of Pten in B cell homeostasis and immunoglobulin class switch recombination. J. Exp. Med. 2003, 197:657-667.
28. Anzelon A.N., Wu H., Rickert R.C. Pten inactivation alters peripheral B lymphocyte fate and reconstitutes CD19 function. Nat. Immunol. 2003, 4:287-294.
29. Rudelius M., Pittaluga S., Nishizuka S., Pham T.H., Fend F., Jaffe E.S., Quintanilla-Martinez L., Raffeld M. Constitutive activation of Akt contributes to the pathogenesis and survival of mantle cell lymphoma. Blood 2006, 108:1668-1676.
30. Uddin S., Hussain A.R., Siraj A.K., Manogaran P.S., Al-Jomah N.A., Moorji A., Atizado V., Al-Dayel F., Belgaumi A., El-Solh H., Ezzat A., Bavi P., Al-Kuraya K.S. Role of phosphatidylinositol 3'-kinase/AKT pathway in diffuse large B-cell lymphoma survival. Blood 2006, 108:4178-4186.
31. Miletic A.V., Anzelon-Mills A.N., Mills D.M., Omori S.A., Pedersen I.M., Shin D.M., Ravetch J.V., Bolland S., Morse H.C., Rickert R.C. Coordinate suppression of B cell lymphoma by PTEN and SHIP phosphatases. J. Exp. Med. 2010, 207:2407-2420.
32. Shen L., Zhang C., Wang T., Brooks S., Ford R.J., Lin-Lee Y.C., Kasianowicz A., Kumar V., Martin L., Liang P., Cowell J., Ambrus J.L. Development of autoimmunity in IL-14alpha-transgenic mice. J. Immunol. 2006, 177:5676-5686.
33. Suzuki A., Kaisho T., Ohishi M., Tsukio-Yamaguchi M., Tsubata T., Koni P.A., Sasaki T., Mak T.W., Nakano T. Critical roles of Pten in B cell homeostasis and immunoglobulin class switch recombination. J. Exp. Med. 2003, 197:657-667.
34. Shen L., Zhang C., Wang T., Brooks S., Ford R.J., Lin-Lee Y.C., Kasianowicz A., Kumar V., Martin L., Liang P., Cowell J., Ambrus J.L. Development of autoimmunity in IL-14{alpha}-transgenic mice. J. Immunol. 2006, 177:5676-5686.
35. Rickert R.C., Roes J., Rajewsky K. B lymphocyte-specific, Cre-mediated mutagenesis in mice. Nucleic Acids Res. 1997, 25:1317-1318.
36. Schmittgen T.D., Livak K.J. Analyzing real-time PCR data by the comparative C(T) method. Nat. Protoc. 2008, 3:1101-1108.
37. Mahadevan D., Chiorean E.G., Harris W.B., Von Hoff D.D., Stejskal-Barnett A., Qi W., Anthony S.P., Younger A.E., Rensvold D.M., Cordova F., Shelton C.F., Becker M.D., Garlich J.R., Durden D.L., Ramanathan R.K. Phase I pharmacokinetic and pharmacodynamic study of the pan-PI3K/mTORC vascular targeted pro-drug SF1126 in patients with advanced solid tumours and B-cell malignancies. Eur. J. Cancer 2012, 48:3319-3327.
38. Garlich J.R., De P., Dey N., Su J.D., Peng X., Miller A., Murali R., Lu Y., Mills G.B., Kundra V., Shu H.K., Peng Q., Durden D.L. A vascular targeted pan phosphoinositide 3-kinase inhibitor prodrug, SF1126, with antitumor and antiangiogenic activity. Cancer Res. 2008, 68:206-215.
39. Monick M.M., Carter A.B., Robeff P.K., Flaherty D.M., Peterson M.W., Hunninghake G.W. Lipopolysaccharide activates Akt in human alveolar macrophages resulting in nuclear accumulation and transcriptional activity of beta-catenin. J. Immunol. 2001, 166:4713-4720.
40. Gustin J.A., Korgaonkar C.K., Pincheira R., Li Q., Donner D.B. Akt regulates basal and induced processing of NF-kappaB2 (p100) to p52. J. Biol. Chem. 2006, 281:16473-16481.
41. Tergaonkar V. NFkappaB pathway: a good signaling paradigm and therapeutic target. Int. J. Biochem. Cell Biol. 2006, 38:1647-1653.
42. Scheidereit C. IkappaB kinase complexes: gateways to NF-kappaB activation and transcription. Oncogene 2006, 25:6685-6705.
43. Ambrus J.L., Fauci A.S. Human B lymphoma cell line producing B cell growth factor. J. Clin. Invest. 1985, 75:732-739.
44. Ambrus J.L., Chesky L., Stephany D., McFarland P., Mostowski H., Fauci A.S. Functional studies examining the subpopulation of human B lymphocytes responding to high molecular weight B cell growth factor. J. Immunol. 1990, 145:3949-3955.
45. Liou H.C., Hsia C.Y. Distinctions between c-Rel and other NF-kappaB proteins in immunity and disease. Bioessays 2003, 25:767-780.
46. Karin M., Lin A. NF-kappaB at the crossroads of life and death. Nat. Immunol. 2002, 3:221-227.
47. Bonizzi G., Karin M. The two NF-kappaB activation pathways and their role in innate and adaptive immunity. Trends Immunol. 2004, 25:280-288.
48. Hayden M.S., Ghosh S. Signaling to NF-kappaB. Genes Dev. 2004, 18:2195-2224.
49. Zang C., Eucker J., Liu H., Coordes A., Lenarz M., Possinger K., Scholz C.W. Inhibition of pan-class I PI3 kinase by NVP-BKM120 effectively blocks proliferation and induces cell death in diffuse large B cell lymphoma. Leuk. Lymphoma 2013, 55:425-434.
50. Reeder C.B., Ansell S.M. Novel therapeutic agents for B-cell lymphoma: developing rational combinations. Blood 2011, 117:1453-1462.